BIOVERATIV INC. Research and Development Expense
BIOVERATIV INC. reported Research and Development Expense of $224.60 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2018-02-14
- BIOVERATIV INC. research and development expense for the quarter ending 2017-12-31 was $83.90M, a 32.75% increase year-over-year.
- BIOVERATIV INC. research and development expense for the quarter ending 2017-09-30 was $70.10M, a 64.17% increase year-over-year.
- BIOVERATIV INC. research and development expense for the quarter ending 2017-06-30 was $33.70M, a 32.46% decline year-over-year.
- BIOVERATIV INC. research and development expense for the quarter ending 2017-03-31 was $36.90M, a 32.04% decline year-over-year.
- BIOVERATIV INC. research and development expense for fiscal 2017 was $224.60M, a 6.90% increase from fiscal 2016.
- BIOVERATIV INC. research and development expense for fiscal 2016 was $210.10M, a 11.31% decline from fiscal 2015.
- BIOVERATIV INC. research and development expense for fiscal 2015 was $236.90M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2017-12-31 | $83.90M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-14 | $154.00M derived: sum of 2 quarters · filed 2018-02-14 | $187.70M derived: sum of 3 quarters · filed 2018-02-14 | $224.60M 10-K · filed 2018-02-14 |
| 2017-09-30 | $70.10M 10-Q · filed 2017-10-27 | $103.80M derived: sum of 2 quarters · filed 2017-10-27 | $140.70M 10-Q · filed 2017-10-27 | $203.90M derived: sum of 4 quarters · filed 2018-02-14 |
| 2017-06-30 | $33.70M 10-Q · filed 2017-08-03 | $70.60M 10-Q · filed 2017-08-03 | $133.80M derived: sum of 3 quarters · filed 2018-02-14 | $176.50M derived: sum of 4 quarters · filed 2018-02-14 |
| 2017-03-31 | $36.90M 10-Q · filed 2017-05-12 | $100.10M derived: sum of 2 quarters · filed 2018-02-14 | $142.80M derived: sum of 3 quarters · filed 2018-02-14 | $192.70M derived: sum of 4 quarters · filed 2018-02-14 |
| 2016-12-31 | $63.20M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-14 | $105.90M derived: sum of 2 quarters · filed 2018-02-14 | $155.80M derived: sum of 3 quarters · filed 2018-02-14 | $210.10M 10-K · filed 2018-02-14 |
| 2016-09-30 | $42.70M 10-Q · filed 2017-10-27 | $92.60M derived: sum of 2 quarters · filed 2017-10-27 | $146.90M 10-Q · filed 2017-10-27 | |
| 2016-06-30 | $49.90M 10-Q · filed 2017-08-03 | $104.20M 10-Q · filed 2017-08-03 | ||
| 2016-03-31 | $54.30M 10-Q · filed 2017-05-12 | |||
| 2015-12-31 | $236.90M 10-K · filed 2018-02-14 |